In a thematic debut, this episode comprises three interviews held with our very own listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver.
Respectively, Pamela Danagher (Terns Pharmaceuticals), Jerry Mabary (Chronwell) and Caitlin Schneider (Sonic Incytes) join Jörn Schattenberg and Roger Green to explore four prominent questions around:
- the “straightjacket” of biopsy
- how we think about “tests” when not classed as “NITs” as compared to biopsy
- how do we all become better centered on patient needs
- the idea of combination therapy
Each guest shares insights which collectively cast invaluable light on how the information featured in Surfing the NASH Tsunami is digested and applied in everyday life.
As the podcast enters its fourth season, and embarks on affiliated journeys like the Rising Tide series, we hope to grow our community engagement. If you enjoy our content, we kindly ask that you submit a review wherever you download our episodes. We also encourage our audience to write us questions and look forward to integrating your on-ground experiences and perspectives in the weekly discourse. Most important of all, we whole-heartedly thank you for your continued support as we set out to put a major dent in Fatty Liver disease in 2023 and beyond.
Stay safe and surf on!
